Eli Lilly (LLY) Stock: Surge as Foundayo Shows Stronger Weight Loss Than Semaglutide

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks

Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies

Eli Lilly and Company has reported findings from an indirect treatment comparison analysing data from the ACHIEVE-3 and PIONEER PLUS studies of its investigational therapy Foundayo against oral semaglutide in adults with type 2 diabetes.

Eli Lilly (LLY) Stock: New Data Shows Foundayo Edge Over Novo’s Ozempic Pill

TLDR Eli Lilly says its oral drug Foundayo beats Novo Nordisk’s Ozempic pill in a new type 2 diabetes comparison. Foundayo’s 17.2 mg dose showed up to 2% more weight loss than Ozempic’s 25 mg pill. Novo’s high dose Ozempic pill isn’t approved in the US for type 2 diabetes yet; an FDA decision is...

Eli Lilly (LLY) Stock: Surge as Foundayo Shows Stronger Weight Loss Than Semaglutide

TLDR Eli Lilly shares gained 0.16% in pre-market trading after new Foundayo data. Foundayo delivered 1.5% greater weight loss than oral semaglutide at 52 weeks. The treatment reduced A1C by 0.3% more than oral semaglutide in the analysis. Lilly used ACHIEVE-3 and PIONEER PLUS data for the indirect comparison. Foundayo could strengthen Lilly’s expanding diabetes [...]